Fanny O’Brien

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar et al. · Muscle & Nerve · 2019 · 247 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease

Bernard Bénichou, Sunita Goyal, Crystal Sung et al. · Molecular Genetics and Metabolism · 2008 · 102 citations

Life Sciences, Biochemistry, Enzymology +4

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

John Vissing, Saiju Jacob, Kenji P. Fujita et al. · Journal of Neurology · 2020 · 97 citations · Full text

Nursing, Neurology, Pharmacotherapy +17

Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth.

Paul Desrosiers, Fanny O’Brien, Sandra L. Blethen · PubMed · 2005 · 84 citations

Medicine, Endocrinology, Pediatrics +17